Real-World Use of Ruxolitinib in Patients with Myelofibrosis and Anemia or Thrombocytopenia at Diagnosis [0.03%]
鲁索利替尼治疗原发性骨髓纤维化合并贫血或血小板减少患者的中国真实世界研究
Jingbo Yu,Emily Bland,Tammy Schuler et al.
Jingbo Yu et al.
Introduction: Ruxolitinib is approved for treatment of myelofibrosis. We evaluated ruxolitinib in patients with anemia (hemoglobin
Sudden Blast Crisis in a Chronic Myeloid Leukemia Patient in Treatment-Free Remission: A Case Report and Literature Review [0.03%]
慢性粒细胞白血病治疗缓解期突发危象的病例报告及文献复习
Qiushi Liang,Zhigang Liu,Yu Wu et al.
Qiushi Liang et al.
Introduction: Treatment-free remission (TFR) has emerged as a new goal in the treatment of chronic myeloid leukemia (CML). TFR is considered a safe intervention because patients who experienced molecular relapse usually r...
Case Reports
Acta haematologica. 2024 Oct 21:1-8. DOI:10.1159/000542153 2024
Published Erratum
Acta haematologica. 2024;147(6):735. DOI:10.1159/000541607 2024
Belantamab Mafodotin in Relapsed/Refractory AL Amyloidosis: Real-World Multi-Center Experience and Review of the Literature [0.03%]
贝尔兰马福多汀治疗复发/难治性AL型淀粉样变病的多中心真实世界经验及文献回顾
Eyal Lebel,Vladimir Vainstein,Paolo Milani et al.
Eyal Lebel et al.
Introduction: Treatment for relapsed/refractory AL amyloidosis (AL) is an unmet need. The safety and efficacy of belantamab mafodotin (BLM) in multiple myeloma are known, whereas in AL data are limited. ...
Intake of Proton Pump Inhibitors Is Associated with a Shorter Time to First Treatment in Early-Stage Chronic Lymphocytic Leukemia [0.03%]
质子泵抑制剂的摄入与早期慢性淋巴细胞性白血病首次治疗时间缩短有关
Tamar Tadmor,Guy Melamed,Hilel Alapi et al.
Tamar Tadmor et al.
Introduction: Proton pump inhibitors (PPIs) are one of the most widely used drugs worldwide [Gut Liver. 2017;11(1):27-37]. The use of PPI has become a common practice and is overprescribed for all patients with cancer inc...
Alessandra Iurlo,Cristina Bucelli,Tamara Intermesoli et al.
Alessandra Iurlo et al.
Introduction: Up to 30% of CML patients will require a therapeutic change during follow-up due to intolerance and/or resistance to first-line tyrosine kinase inhibitor (TKI) approach. In this context, bosutinib (BOS) has ...
Role of Autologous Transplant in Newly Diagnosed Multiple Myeloma Patients Treated with Novel Triplets: A Systematic Review and Meta-Analysis [0.03%]
自体移植在初诊多发性骨髓瘤患者新型三联疗法中的作用：系统评价和 meta 分析
Irina Amitai,Ronit Gurion,Pia Raanani et al.
Irina Amitai et al.
Introduction: High-dose therapy with melphalan followed by autologous stem cell transplant in the upfront setting (upfront ASCT) has significantly improved clinical outcomes of myeloma patients and become the standard of ...
Beneficial Effect of Integrated Nutritional Interventions in Patients with Hematological Diseases Undergoing Hematopoietic Stem Cell Transplant [0.03%]
血液病患者造血干细胞移植的综合营养干预效果研究
Mimi Geng,Zihui Sun
Mimi Geng
Introduction: The nutritional status of patients undergoing hematopoietic stem cell transplantation (HSCT) is critically important. This study aimed to assess the impact of comprehensive nutritional interventions on the w...
Outcomes of Fedratinib in Routine Treatment of Ruxolitinib-Resistant or -Refractory Patients with Primary and Post-Polycythemia Vera or Essential Thrombocythemia Myelofibrosis: A Nationwide Retrospective Study [0.03%]
费达那替尼治疗鲁索利替尼耐药/难治性原发和继发真性红细胞增多症或必要血小板增多症骨髓纤维化的疗效：全国回顾性研究
Adrian Duek,Alexandra Tzinman,Kira Maziuk et al.
Adrian Duek et al.
Introduction: In recent years, fedratinib, a selective JAK2 inhibitor, has emerged as a potential therapeutic option for patients who have failed or are intolerant to ruxolitinib. Despite the promising results observed in...
Real-World Impact of Routine Addition of Antithymocyte Globulin to Standard GVHD Prophylaxis in Myeloablative Unrelated Donor Transplants: Important Gains in Graft-versus-Host Disease Prevention though No Difference in Overall Survival [0.03%]
抗胸腺细胞免疫球蛋白作为标准移植物抗宿主病预防方案的一部分应用于匹配单倍型相合移植：对移植物抗宿主病的良好控制但总体生存率无改善
Ni Bai,Wasithep Limvorapitak,Robert Henderson et al.
Ni Bai et al.
Introduction: Antithymocyte globulin (ATG) has been demonstrated to reduce the incidence of graft-versus-host disease (GVHD); however, it remains controversial whether these gains are offset by an increase in relapse. ...